In just the past five years, significant changes have occurred in how new drugs come to market. Demands for real world evidence and patient-reported outcomes are changing how and when new drugs file for approval. Accountable care organizations (ACOs), integrated delivery networks (IDNs), advocacy groups, and payers are increasingly flexing their muscles. Yesteryear's tried-and-true paths to commercialization have developed new twists and turns, and the ecosystem has become more complicated.
Check out this article in BioPharma Dive by Dominic Marasco, RPh, Executive Vice President for Global Business Development and Commercial Solutions at Syneos Health, for a few of the most important ways our world has changed.